Aurobindo Pharma Ltd. announced on Friday that its subsidiary, Aurolife Pharma LLC, has received a Form 483 with 11 observations from the US Food and Drug Administration following an inspection of its Raleigh plant in North Carolina, US.
The inspection took place from March 24 to April 10, 2025, according to a regulatory filing by the company.
At the conclusion of the inspection, the FDA issued the Form 483, noting 11 procedural observations. Aurobindo Pharma stated that it will provide a detailed response to the FDA within the required timeline, addressing each observation with appropriate corrective and preventive measures.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Asserting that it is committed to maintaining the highest standards of quality and compliance across all its operations, Aurobindo Pharma said, "We do not expect this development to have any material impact on the current business operations or existing supplies from this facility."
Shares of Aurobindo Pharma closed 2.31% higher at Rs 1,082.45 apiece on the NSE, compared to a 1.92% rise in the benchmark Nifty 50. The stock has fallen 0.55% in the last 12 months and 18.89% year-to-date.
Out of 29 analysts tracking the company, 22 have a 'buy' rating on the stock, three suggest 'hold' and four recommend 'sell' according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 35.2%.
(With PTI Inputs)
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
